Daniel Spernat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel Spernat has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Anne‐Maree Haynes
Prostate Cancer Group, Cancer Research Programme, Garvan Institute of Medical Research
1 shared publicationBridget Heijkoop
Urology Department, The Queen Elizabeth Hospital, The University of Adelaide, Level 7A, 28 Woodville rd, Woodville South, SA, 5011, Australia
1 shared publicationCarlo Yuen
Department of Urology, St Vincent's Hospital
1 shared publicationChanghong Yu
Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA
1 shared publicationChristine Su Li Lai
Department of Breast and Endocrine Surgery, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia
1 shared publicationDavid Ca Walsh
University of Adelaide, Queen Elizabeth Hospital, South Australia, Australia
1 shared publication
Latest Publications
- Open Access
- 16 July 2022
- Published by Jaypee Brothers Medical Publishing in World Journal of Endocrine Surgery
- Vol. 14 (1) , 15-20
Retroperitoneal Paraganglioma often Atypical: Short Case Series and Review of the Literature
- 16 July 2022
- Published by Jaypee Brothers Medical Publishing in World Journal of Endocrine Surgery
- Vol. 14 (1) , 15-20
Open AccessRetroperitoneal Paraganglioma often Atypical: Short Case Series and Review of the Literature
- Open Access
- 30 October 2019
- Published by Springer Nature in Systematic Reviews
- Vol. 8 (1) , 1-5
Effectiveness and safety of inpatient versus extended venous thromboembolism (VTE) prophylaxis with heparin following major pelvic surgery for malignancy: protocol for a systematic review
Background: Venous thromboembolism (VTE) is a common postoperative complication associated with significant morbidity and mortality. The use of prophylactic heparin postoperatively reduces this risk, and the use of extended duration prophylaxis is becoming increasingly common. Malignancy and pelvic surgery both independently further increase the risk of postoperative VTE and patients undergoing major pelvic surgery for malignancy are at particularly high risk of VTE. However, the optimum duration of prophylaxis specifically in this population currently remains unclear. Methods: We will conduct a systematic review of literature in accordance with the Cochrane Handbook for Systematic Reviews of Interventions (Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0.,2011) to evaluate current evidence of the effectiveness and safety of inpatient versus extended VTE prophylaxis with heparin (all forms) following major pelvic surgery for malignancy. We will search PubMed, EMBASE, and the Cochrane Library. Regarding safety, Food and Drug Administration (FDA), and Therapeutic Goods Administration (TGA) websites will be searched, including all levels of evidence. Results will be the postoperative timeframe in which a VTE event can be considered to have been provoked by the surgery, and the number of patients needed to treat with both inpatient and extended prophylaxis to prevent a VTE event in this timeframe, comparing these to determine if there is a significant benefit from extended prophylaxis. Discussion: This systematic review will aim to identify the postoperative period in which patients undergoing major pelvic surgery for malignancy are at further increased risk of VTE as a result of their surgery and the optimum duration of heparin VTE prophylaxis with heparin to reduce this risk. Determining this will allow evidence-based recommendations to be made for the optimum duration of heparin VTE prophylaxis post major pelvic surgery for malignancy, leading to improved standards of care that are consistent between different providers and institutions. Systematic review registration: In accordance with guidelines, our systematic review was submitted to PROSPERO for consideration of registration on 16/12/17 and was registered on 12/1/18 with the registration number CRD42018068961, and it was last updated on December 1, 2018.
- 30 October 2019
- Published by Springer Nature in Systematic Reviews
- Vol. 8 (1) , 1-5
Open AccessEffectiveness and safety of inpatient versus extended venous thromboembolism (VTE) prophylaxis with heparin following major pelvic surgery for malignancy: protocol for a systematic review
Background: Venous thromboembolism (VTE) is a common postoperative complication associated with significant morbidity and mortality. The use of prophylactic heparin postoperatively reduces this risk, and the use of extended duration prophylaxis is becoming increasingly common. Malignancy and pelvic surgery both independently further increase the risk of postoperative VTE and patients undergoing major pelvic surgery for malignancy are at particularly high risk of VTE. However, the optimum duration of prophylaxis specifically in this population currently remains unclear. Methods: We will conduct a systematic review of literature in accordance with the Cochrane Handbook for Systematic Reviews of Interventions (Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0.,2011) to evaluate current evidence of the effectiveness and safety of inpatient versus extended VTE prophylaxis with heparin (all forms) following major pelvic surgery for malignancy. We will search PubMed, EMBASE, and the Cochrane Library. Regarding safety, Food and Drug Administration (FDA), and Therapeutic Goods Administration (TGA) websites will be searched, including all levels of evidence. Results will be the postoperative timeframe in which a VTE event can be considered to have been provoked by the surgery, and the number of patients needed to treat with both inpatient and extended prophylaxis to prevent a VTE event in this timeframe, comparing these to determine if there is a significant benefit from extended prophylaxis. Discussion: This systematic review will aim to identify the postoperative period in which patients undergoing major pelvic surgery for malignancy are at further increased risk of VTE as a result of their surgery and the optimum duration of heparin VTE prophylaxis with heparin to reduce this risk. Determining this will allow evidence-based recommendations to be made for the optimum duration of heparin VTE prophylaxis post major pelvic surgery for malignancy, leading to improved standards of care that are consistent between different providers and institutions. Systematic review registration: In accordance with guidelines, our systematic review was submitted to PROSPERO for consideration of registration on 16/12/17 and was registered on 12/1/18 with the registration number CRD42018068961, and it was last updated on December 1, 2018.
- Open Access
- 29 November 2012
- Published by Wiley in BJU International
- Vol. 110 (S4) , 71-76
High‐dose rate brachytherapy compared with open radical prostatectomy for the treatment of high‐risk prostate cancer: 10 year biochemical freedom from relapse
Objective To compare long‐term biochemical control of high‐risk prostate cancer in those men receiving high‐dose rate brachytherapy (HDRB) and radical prostatectomy (RP). Patients and methods The 10‐year biochemical freedom from relapse (BFR) was calculated for 243 patients who underwent either RP or combined therapy with HDRB + external beam radiotherapy + androgen deprivation between 1998 and 2000. Inclusion criteria: clinical stage ≥ T2b, or Gleason sum ≥ 8, or PSA level of > 20 ng/mL. Groups were appraised using the Kattan nomogram for surgery to calculate progression‐free probability (PFP). Results For the RP group (153 patients) the median PSA level was 8.1 ng/mL and the median age was 62.2 years. The median 5‐ and 10‐year predicted PFP for RP was 64% and 56 %, respectively. The 5‐ and 10‐year BFR was 65.5% and 55.4%. There was no significant difference between the predicted and the actual PFP for the RP group ( P = 0.525). For HDRB group (90 patients). The median PSA level was 14.2 ng/mL and the median age was 67.6 years. The median 5‐ and 10‐year predicted PFP for HDRB was 46% and 35%, respectively. The 5‐ and 10‐year BFR was 79.6% and 53.6%. There was a significant improvement between the actual and the predicted PFP for the HDRB group ( P = 0.002). Conclusions Amongst a high‐risk cohort, patients undergoing RP performed as predicted by the pre‐treatment surgical nomogram, whereas the patients undergoing HDRB performed significantly better than was predicted by the surgical nomogram at 10 years.
- 29 November 2012
- Published by Wiley in BJU International
- Vol. 110 (S4) , 71-76
Open AccessHigh‐dose rate brachytherapy compared with open radical prostatectomy for the treatment of high‐risk prostate cancer: 10 year biochemical freedom from relapse
Objective To compare long‐term biochemical control of high‐risk prostate cancer in those men receiving high‐dose rate brachytherapy (HDRB) and radical prostatectomy (RP). Patients and methods The 10‐year biochemical freedom from relapse (BFR) was calculated for 243 patients who underwent either RP or combined therapy with HDRB + external beam radiotherapy + androgen deprivation between 1998 and 2000. Inclusion criteria: clinical stage ≥ T2b, or Gleason sum ≥ 8, or PSA level of > 20 ng/mL. Groups were appraised using the Kattan nomogram for surgery to calculate progression‐free probability (PFP). Results For the RP group (153 patients) the median PSA level was 8.1 ng/mL and the median age was 62.2 years. The median 5‐ and 10‐year predicted PFP for RP was 64% and 56 %, respectively. The 5‐ and 10‐year BFR was 65.5% and 55.4%. There was no significant difference between the predicted and the actual PFP for the RP group ( P = 0.525). For HDRB group (90 patients). The median PSA level was 14.2 ng/mL and the median age was 67.6 years. The median 5‐ and 10‐year predicted PFP for HDRB was 46% and 35%, respectively. The 5‐ and 10‐year BFR was 79.6% and 53.6%. There was a significant improvement between the actual and the predicted PFP for the HDRB group ( P = 0.002). Conclusions Amongst a high‐risk cohort, patients undergoing RP performed as predicted by the pre‐treatment surgical nomogram, whereas the patients undergoing HDRB performed significantly better than was predicted by the surgical nomogram at 10 years.